Apellis Pharmaceuticals Inc (APLS)
27.73
+0.24
(+0.87%)
USD |
NASDAQ |
Nov 21, 16:00
27.73
0.00 (0.00%)
After-Hours: 20:00
Apellis Pharmaceuticals Gross Profit Margin (Quarterly): 82.95% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 82.95% |
| June 30, 2024 | 88.43% |
| March 31, 2024 | 88.27% |
| December 31, 2023 | 86.40% |
| September 30, 2023 | 79.70% |
| June 30, 2023 | 91.18% |
| March 31, 2023 | 82.59% |
| December 31, 2022 | 87.09% |
| Date | Value |
|---|---|
| September 30, 2022 | 93.74% |
| June 30, 2022 | 99.50% |
| March 31, 2022 | 91.33% |
| December 31, 2021 | 91.62% |
| September 30, 2021 | 97.36% |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 89.98% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
79.70%
Minimum
Sep 2023
99.50%
Maximum
Jun 2022
89.30%
Average
89.21%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 74.73% |
| Ionis Pharmaceuticals Inc | 99.20% |
| EyePoint Pharmaceuticals Inc | 93.01% |
| Cassava Sciences Inc | -- |
| Macrogenics Inc | 98.31% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -104.7% |
| Return on Assets | -29.46% |
| Return on Invested Capital | -52.47% |
| Profit Margin (Quarterly) | -29.19% |
| Operating Margin (Quarterly) | -24.02% |
| Return on Net Operating Assets | -55.90% |